JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Exploring Programmed Cell Death-Related Biomarkers and Disease Therapy Strategy in Nasopharyngeal Carcinoma Using Transcriptomics

  • 0Department of Otorhinolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital of Ningbo University, 315040 Ningbo, Zhejiang, China.
Frontiers in Bioscience (landmark Edition) +

|

July 31, 2024

|

July 31, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies FN1 and MUC1 as key biomarkers for nasopharyngeal carcinoma (NPC) by analyzing programmed cell death (PCD) related genes. These biomarkers show potential for improving NPC diagnosis and treatment strategies.

Area Of Science

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background

  • Uncontrolled cellular proliferation drives cancer progression and mortality.
  • Programmed cell death (PCD) is crucial for maintaining cellular homeostasis and quality control.
  • PCD mechanisms offer potential as biomarkers for disease diagnosis and therapeutic targeting.

Purpose Of The Study

  • To identify novel biomarkers for nasopharyngeal carcinoma (NPC) by analyzing programmed cell death (PCD)-related genes.
  • To investigate the role of identified biomarkers in NPC progression and cellular functions.
  • To explore potential therapeutic strategies targeting the identified biomarkers.

Main Methods

  • RNA-sequencing data from NPC patients were analyzed to identify differentially expressed genes (DEGs).
  • Machine learning algorithms (Lasso, SVM) and bioinformatics tools (STRING, Cytoscape) were employed for biomarker screening and protein interaction analysis.
  • In vitro assays (wound healing, Transwell) and molecular docking were performed to validate biomarker function and potential drug interactions.

Main Results

  • 800 DEGs were identified, including 59 PCD-related DEGs associated with NPC progression and key signaling pathways (PI3K-Akt, TGF-β, IL-17).
  • FN1 and MUC1 were identified as reliable NPC biomarkers with high diagnostic accuracy (AUC > 0.9).
  • FN1 and MUC1 overexpression correlated with PCD pathways, enhanced NPC cell migration and invasion, and showed binding capacity with potential drug molecules.

Conclusions

  • FN1 and MUC1 are validated as reliable biomarkers for nasopharyngeal carcinoma (NPC).
  • These biomarkers are significantly associated with PCD-related pathways and cellular behaviors in NPC.
  • The findings support the development of novel NPC diagnostic and therapeutic strategies targeting FN1 and MUC1.

Keywords: